SRSF2 and myelodysplastic syndrome: A combination of SRSF2 status and IPSS assessment might improve prognostic evaluation for patients with low- or intermediate-1-IPSS risk MDS, and patients with SRSF2 mutations might benefit from more intensive treatment.